← All Hillevax, INC filings

Hillevax, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

HLVX
Hillevax, INC
10-K: HilleVax Reports Disappointing Phase 2b Results, Shifts Focus to Strategic Alternatives
HilleVax's Phase 2b trial for its norovirus vaccine candidate failed to meet its primary endpoint, leading to a strategic shift and workforce reduction.
HLVX
Hillevax, INC
10-K: HilleVax 10-K Filing: Norovirus Vaccine Development and Financial Overview
HilleVax's 10-K filing details their progress in developing a norovirus vaccine, HIL-214, and their financial status as a clinical-stage biopharmaceutical company.